Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Fresenius Settles Seven Tocilizumab Patent IPRs with Chugai and Roche 

Oct 27, 2022

In October 2022, Fresenius Kabi entered into a confidential settlement agreement with Chugai and Roche, which resulted in the termination of seven Inter Partes Review proceedings in relation to tocilizumab patentsThe IPRs were commenced by Fresenius in 2021 and 2022.  At the time of settlement, the PTAB had instituted six of the IPRs, with one pending institutionThe IPRs were IPR2021-01024, IPR2021-01025 , IPR2021-01288, IPR2021-01336, IPR2021-01542, IPR2022-00201 and IPR2022-01065.